key: cord-0745138-pawxyu03
authors: Romano, Ciro; Esposito, Sergio; Donnarumma, Giovanna; Marrone, Aldo
title: DETECTION OF NEUTRALIZING ANTI-SARS-CoV-2 ANTIBODIES IN COMMON VARIABLE IMMUNODEFICIENCY PATIENTS FOLLOWING IMMUNIZATION WITH mRNA VACCINES
date: 2021-08-02
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.07.026
sha: 8739b7a133df2e817532bd428454bb28df82b963
doc_id: 745138
cord_uid: pawxyu03

nan

Common variable immunodeficiency (CVID) is a rare disorder, occurring in roughly 2-4/100000 individuals in the general population. However, it is the most common symptomatic primary immunodeficiency disorder in adults and may account for a significant proportion of patients in specialized immunology clinics. The etiology is unknown; diagnosis relies on multiple criteria as no single clinical manifestation or laboratory test can aid in recognizing this entity 1 . Specifically, CVID may be diagnosed in case of a marked decrease of IgG (at least 2 SD below the mean for age) and a marked decrease in IgM or IgA, along with all of the following criteria: 1) onset of immunodeficiency at greater than 2 years of age; 2) absent isohemagglutinins and/or poor response to vaccines; and 3) exclusion of other possible causes of hypogammaglobulinemia 1 . Antibody production is always impaired in CVID, as a result of primary B-cell dysfunction or from lack of T cell help for antibody production 1 .

The current pandemic of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 represents an unprecedented challenge for healthcare systems across the world 2 , but the ongoing global mass vaccination against SARS-CoV-2 may help reduce the hospital burden worldwide. CVID patients, however, may not be included into vaccination programs because of the common perception that they are not responsive to vaccination 1 . In countries like Italy, where general practitioners are in charge of the recruitment of "fragile" patients into vaccination programs, it is paramount to address the issue of the effectiveness of COVID-19 vaccines in primary immunodeficiency patients, also considering the low awareness about this peculiar group of diseases among physicians not specializing in clinical immunology 3 . Therefore, in order to establish whether SARS-CoV-2 vaccination may be meaningful in CVID individuals, we investigated whether these patients could generate protective antibodies against SARS-CoV-2 following administration of mRNA vaccines 4 and compared the outcome in healthy subjects from hospital staff undergoing COVID-19 vaccination.

Five patients (4 F, 1 M, median age 54 years) with CVID (median age at diagnosis: 35 years) on monthly i.v. immunoglobulin replacement therapy agreed to receive a mRNA vaccine 4 . Serum SARS-CoV-2 antibodies were measured in all patients immediately prior to vaccination and the next IgG infusion (because of the possibility of antibodies against SARS-CoV-2 in commercial i.v. immunoglobulin preparations 5 ) and 30 days after the second vaccine jab, again just before the next IgG infusion. Adverse effects were recorded for all patient after each vaccine dose administration.

Comorbidities and immunologic features were also registered. Patient #4 (Table 1 ) suffered from a mild form of the natural infection with SARS-CoV-2 four months before the vaccination. At that time, this patient only complained of fever (38°C) for two days and cough but it took nearly 4 weeks for his nasopharyngeal swab to turn negative on molecular recognition of SARS-CoV-2.

Among the 5 patients subjected to vaccination, he was also the only one to show naturally-occurring virus-specific neutralizing antibodies, which greatly increased following completion of the vaccination schedule ( Table 1) Overall, our experience shows that SARS-CoV-2 vaccination is safe and effective even in patients with primary antibody deficiencies. However, as inferred by the only patient who did not show an antibody response to vaccination, production of neutralizing immunoglobulins may at least require preservation of the B lymphocyte population. Whether the serum levels measured in CVID patients are able to fully protect these subjects from mild or severe manifestations of COVID-19 is currently unknown, as there are not yet ad hoc studies. Further complicating things, CVID patients are known to be able to even produce antibodies at normal titers, but these antibodies may have poor avidity with impaired opsonophagocytic function 7 . Likewise, comparing serum levels of anti-SARS-CoV-2 antibodies between CVID patients and immunocompetent subjects to evaluate the magnitude of vaccination efficacy may as well be meaningless, since the level of neutralizing antibodies required to confer protection has not been definitively established 8 . Indeed, serum levels of anti-SARS-CoV-2 antibodies appeared to be overall more elevated in healthy hospital personnel than in CVID patients, but, again, the clinical significance of this difference is currently unknown 8 . Interestingly, the only patient (#4) with prior, naturally-acquired immunization against SARS-CoV-2 had an impressive rise in the titers of neutralizing antibodies following vaccination; thus, if prior immunization is a prerequisite for remarkable antibody responses following vaccination, it may theoretically be anticipated that a further vaccine jab would probably significantly enhance the protective antibody response in the remaining patients as well. Our data are fully consistent with those recently reported by two other studies of mRNA COVID-19 vaccine immunogenicity in primary immunodeficiency patients 9,10 . In both reports, all CVID patients but two (19 total, 6 and 13 in the two studies 9,10 , respectively) were able to mount specific antibody responses following vaccination. Accordingly, patients with absence of B cells (i.e., XLA patients) failed to show production of neutralizing antibodies against SARS-CoV-2 9,10 . However, these patients did produce robust anti-viral cellular responses 10 , which still may justify vaccination. Likewise, adverse effects to vaccination were mild in both studies. Taken together, the results of our and these two other studies strongly support the notion that CVID patients must be included in COVID-19 vaccination programs because of the ability of mRNA vaccines to safely induce production of neutralizing antibodies in this category of patients. 

International Consensus Document (ICON): Common Variable Immunodeficiency Disorders

Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A review

Evaluation of awareness about primary immunodeficiencies among physicians before and after implementation of the educational program: A longitudinal study

SARS-CoV-2 vaccines

Detection of antibodies against SARS-CoV-2 both in plasma pools for fractionation and in commercial intravenous immunoglobulins produced from plasma collected in Italy during the pandemic. Blood Transfus. 2021 online ahead of print

COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines